These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7477118)

  • 61. Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer.
    Nimisha ; Saluja SS; Sharma AK; Nekarakanti PK; Apurva ; Kumar A; Ahmad E; Husain SA
    J Clin Exp Hepatol; 2024; 14(5):101410. PubMed ID: 38716375
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Systematic Review of the Heterogenous Gene Expression Patterns Associated with Multidrug Chemoresistance in Conventional Osteosarcoma.
    Mthethwa PG; Marais LC; Ramsuran V; Aldous CM
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107591
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells.
    Giacomini I; Cortini M; Tinazzi M; Baldini N; Cocetta V; Ragazzi E; Avnet S; Montopoli M
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900165
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin.
    Cortini M; Macchi F; Reggiani F; Vitale E; Lipreri MV; Perut F; Ciarrocchi A; Baldini N; Avnet S
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831562
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review.
    Tippett VL; Tattersall L; Ab Latif NB; Shah KM; Lawson MA; Gartland A
    Oncogene; 2023 Jan; 42(4):259-277. PubMed ID: 36434179
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
    Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FT-IR Spectral Signature of Sensitive and Multidrug-Resistant Osteosarcoma Cell-Derived Extracellular Nanovesicles.
    Perut F; Graziani G; Roncuzzi L; Zini N; Avnet S; Baldini N
    Cells; 2022 Feb; 11(5):. PubMed ID: 35269400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Exosomal Long Non-Coding RNA ANCR Mediates Drug Resistance in Osteosarcoma.
    Hu X; Wen Y; Tan LY; Wang J; Tang F; Wang YT; Zheng CX; Zhang YQ; Gong TJ; Min L
    Front Oncol; 2021; 11():735254. PubMed ID: 35096563
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival.
    Casanova JM; Almeida JS; Reith JD; Sousa LM; Fonseca R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885185
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rutaecarpine Increases Anticancer Drug Sensitivity in Drug-Resistant Cells through MARCH8-Dependent ABCB1 Degradation.
    Zou T; Zeng C; Qu J; Yan X; Lin Z
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572328
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
    Serra M; Hattinger CM; Pasello M; Casotti C; Fantoni L; Riganti C; Manara MC
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572110
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.
    Hattinger CM; Patrizio MP; Fantoni L; Casotti C; Riganti C; Serra M
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207685
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
    Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma.
    Li J; Qin B; Huang M; Ma Y; Li D; Li W; Guo Z
    Front Immunol; 2021; 12():665106. PubMed ID: 33995397
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.
    Marchandet L; Lallier M; Charrier C; Baud'huin M; Ory B; Lamoureux F
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33567616
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sarcoma treatment in the era of molecular medicine.
    Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
    EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
    Lilienthal I; Herold N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects.
    Pushpam D; Garg V; Ganguly S; Biswas B
    Onco Targets Ther; 2020; 13():5093-5112. PubMed ID: 32606731
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
    Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
    [TBL] [Abstract][Full Text] [Related]  

  • 80. GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.
    Chulanetra M; Morchang A; Sayour E; Eldjerou L; Milner R; Lagmay J; Cascio M; Stover B; Slayton W; Chaicumpa W; Yenchitsomanus PT; Chang LJ
    Am J Cancer Res; 2020; 10(2):674-687. PubMed ID: 32195035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.